Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | IDO1 | P14902 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MDM4 | O15151 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | TNF | P01375 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | TDO2 | P48775 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13402442 | 1.00 | HDAC1 (0.54) | HDAC1HDAC2IDO1KMT2AMDM4 | |
| SCHEMBL28527138 | 1.00 | HDAC1 (0.54) | HDAC1HDAC2IDO1KMT2AMDM4 | |
| SCHEMBL29397673 | 1.00 | HDAC1 (0.54) | HDAC1HDAC2IDO1KMT2AMDM4 | |
| SCHEMBL11912033 | 1.00 | HDAC1 (0.54) | HDAC1HDAC2IDO1KMT2AMDM4 | |
| SCHEMBL29555721 | 0.91 | HDAC1 (0.57) | HDAC1HDAC2IDO1KMT2AMDM4 | |
| SCHEMBL377964 | 0.91 | HDAC1 (0.57) | HDAC1HDAC2IDO1KMT2AMDM4 | |
| SCHEMBL392598 | 0.91 | HDAC1 (0.57) | HDAC1HDAC2IDO1KMT2AMDM4 | |
| SCHEMBL15982313 | 0.91 | HDAC1 (0.57) | HDAC1HDAC2IDO1KMT2AMDM4 | |
| SCHEMBL16167663 | 0.90 | CTSK (0.47) | HDAC1HDAC2IDO1KMT2ATNF | |
| SCHEMBL18718108 | 0.90 | CASP3 (0.51) | HDAC1HDAC2IDO1KMT2AMDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658667-A1 | CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY | Merck Sharp & Dohme LLC (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20240287138-A1 | CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY | MERCK SHARP & DOHME LLC | 2024-08-29 | — | — | US | disclosed |
| WO-2024163691-A1 | CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY | MERCK SHARP & DOHME LLC (US) | 2024-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287138-A1 | CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY | TNF, TNFRSF1A, CD40 | HDAC1 3288/4885HDAC2 4596/4885IDO1 2979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.